Asia-Pacific Ocular Pain Market, By Disease Type (Ocular Pain with Eye Diseases and Ocular Pain without Primary Eye Diseases), Type (Diagnosis and Treatment), Application (Conjunctivitis, Corneal Abrasion, Blepharitis, Sty, Iritis, Sinusitis, Migraines, Glaucoma, and Others), Route of Administration (Topical, Periocular, Intraocular, Oral and Others), Drug Type (Prescription and Over the Counter), Population Type (Adults and Geriatric), End User (Hospitals, Specialty Clinics, Home Healthcare Settings, Ophthalmology Centers, Ambulatory Surgical Centers, and Others), Distribution Channel (Direct Tender, Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), Country (China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, Vietnam and Rest of Asia-Pacific) – Industry Trends and Forecast to 2028.
Market Analysis and Insights: Asia-Pacific Ocular Pain Market
Asia-Pacific ocular pain market is expected to grow in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with the highest CAGR of 9.0% in the forecast period of 2021 to 2028 and is expected to reach USD 322.76 million by 2028. Increasing unhygienic and sedentary lifestyle acts as a driver for the Asia-Pacific ocular pain market growth.
Ocular pain also, known as eye pain, commonly occurs due to mild irritation, but it is rarely a symptom of a serious condition. Mostly the pain resolves without medicine or further treatment, and it recovers by the self-immune system. However, ocular pain with underlying primary ophthalmic disorders requires timely treatment. Eye pains are generally categorized under two categories, such as ocular pain, which occurs over the eye's surface, creating sensations of scratching, burning, or itching. They are caused due to a person’s eyelashes, foreign objects, infection, or trauma. Often ocular pain is treated with eye drops and topical steroids or NSAIDs. Ocular pain occurs with underlying primary eye diseases like conjunctivitis, contact lens irritation, corneal abrasion, injury, blepharitis, and sty. The other advanced treatments, like stimulation therapies, are also used for severe neuro ocular pain, appropriately diagnosed.
Increasing unhygienic and sedentary lifestyles, rising prevalence of ophthalmic disorders, and ocular pain act as drivers for the Asia-Pacific ocular pain market. The increasing awareness among people for eye-related diseases and growing cases of ocular migraine is further boosting the market growth. The side effects of eye treatment medicines and the high cost of eye treatment and medication are restraining the growth of the Asia-Pacific ocular pain market. Increasing research and development activities, rising healthcare expenditure and disposable income, and a growing geriatric population act as opportunities for the Asia-Pacific ocular pain market. Lack of healthcare facilities for eye treatment and stringent regulatory framework poses a challenge for the Asia-Pacific ocular pain market growth.
The Asia-Pacific ocular pain market report provides details of market share, new developments, and product pipeline analysis, the impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the ocular pain market scenario, contact Data Bridge Market Research for an Analyst Brief; our team will help you create a revenue impact solution to achieve your desired goal.
Asia-Pacific Ocular Pain Market Scope and Market Size
Asia-Pacific ocular pain market is segmented based on disease type, type, applications, route of administration, drug type, population type, end user, and distribution channel. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of disease type, the Asia-Pacific ocular pain market is segmented into ocular pain with eye diseases and ocular pain without primary eye diseases. In 2021, the ocular pain with eye diseases segment is expected to dominate the ocular pain market due to rising awareness about ophthalmic conditions among the public.
- On the basis of type, the Asia-Pacific ocular pain market is segmented into diagnosis and treatment. In 2021, the diagnosis segment is expected to dominate the market as research activities in Asia countries and institutes are surging.
- On the basis of application, the Asia-Pacific ocular pain market is segmented into conjunctivitis, corneal abrasion, blepharitis, sty, iritis, sinusitis, migraines, glaucoma, and others. In 2021, the glaucoma segment is expected to dominate the market as the disease's prevalence is high in developing countries of the region.
- On the basis of route of administration, the Asia-Pacific ocular pain market is segmented into topical, periocular, intraocular, oral, and others. In 2021, the topical segment is expected to dominate the market due to high patient compliance.
- On the basis of drug type, the Asia-Pacific ocular pain market is segmented into prescription and over the counter. In 2021, the prescription segment is expected to dominate the market due to heavy stringent regulatory administrations over the region.
- On the basis of population type, the Asia-Pacific ocular pain market is segmented into adults and geriatric. In 2021, the adults segment is expected to dominate the market due to multiple gadgets and less eye care protection.
- On the basis of end user, the Asia-Pacific ocular pain market is segmented into hospitals, specialty clinics, home healthcare, ophthalmology centers, ambulatory surgical centers, and others. In 2021, the hospitals segment is expected to dominate the market due to high healthcare expenditure and hospital construction.
- On the basis of distribution channel, the Asia-Pacific ocular pain market is segmented into direct tender, hospital pharmacy, retail pharmacy, online pharmacy, and others. In 2021, the direct tender segment is expected to dominate the market as they specifically provide products per customers' needs with user benefits.
Asia-Pacific Ocular Pain Market Country Level Analysis
Asia-Pacific ocular pain market is analyzed, and market size information is provided by the country, disease type, type, applications, route of administration, drug type, population type, end user, and distribution channel as referenced above.
The countries covered in the Asia-Pacific ocular pain market report are China, South Korea, Japan, India, Australia, Singapore, Malaysia, Indonesia, Thailand, Philippines, and the Rest of Asia-Pacific.
The prescription segment in Japan of the Asia-Pacific region is expected to grow with the highest growth rate in the forecast period of 2021 to 2028 because of increasing cases of ophthalmic disorders. The prescription segment in China is the second dominating market owing to the increasingly sedentary lifestyle of people. India is the third leading market in the Asia-Pacific region. The prescription segment is expected to dominate in this country due to the highest number of ophthalmology hospitals.
The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, regulatory acts, and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Asia-Pacific brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of sales channels are considered while providing forecast analysis of the country data.
Growing Strategic Activities by Major Market Players to Enhance the Awareness for Ocular Pain Treatment is Boosting the Market Growth of the Asia-Pacific Ocular Pain Market
Asia-Pacific ocular pain market also provides you with a detailed market analysis for every country's growth in the particular market. Additionally, it provides detailed information regarding the market players’ strategy and their geographical presence. The data is available for the historical period 2010 to 2019.
Competitive Landscape and Asia-Pacific Ocular Pain Market Share Analysis
Asia-Pacific ocular pain market competitive landscape provides details by the competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, production sites and facilities, company strengths and weaknesses, product launch, product trials pipelines, product approvals, patents, product width, and breadth, application dominance, technology lifeline curve. The above data points provided are only related to the company’s focus on the Asia-Pacific ocular pain market.
The major companies which are dealing in the Asia-Pacific ocular pain market are Johnson & Johnson Services, Inc., Pfizer Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., AERIE PHARMACEUTICALS, INC., Sun Pharmaceutical Industries Ltd., Bausch & Lomb Incorporated, Novartis AG, Allergan (An AbbVie Company)., Formosapharma Pharmaceutical Inc., and among other domestic players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
Many contracts and agreements are also initiated by companies worldwide, which accelerate the Asia-Pacific ocular pain market.
For instance,
- In September 2021, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., announced that the company participated in a virtual fireside chat at the Morgan Stanley 19th Annual Conference. This helped company in gaining attraction of more Asia-Pacific customers
- In May 2019, Pfizer Inc. expanded its business by opening a new manufacturing facility in Andover, Massachusetts. The company has adopted this initiative to boost up the manufacturing of pharmaceutical products to improve patient’s treatment options. This initiative allowed the company to build up a strong partnership with the research and development manufacturing teams
Collaboration, product launch, business expansion, award and recognition, joint ventures, and other strategies by the market player enhance the company's footprints in the ocular pain market, which also benefits the organization’s profit growth.
SKU-